Addex Therapeutics vs Altimmune
ADXN and ALT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADXN and ALT compare
Altimmune scores higher on the StockData Score (4 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | ALT |
|---|---|---|
| Size and price | ||
| Market cap | – | $375M |
| Share price | $2.89 | $1.93 |
| Change, 1 year | −66.1% | −54.7% |
| Change, 5 years | −98.0% | −81.7% |
| Beta (5Y) | 0.83 | 1.10 |
| Employees | 3 | 13 |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.8× |
| FCF yield | – | −20.4% |
| Growth | ||
| Revenue growth (TTM) | −92.6% | – |
| Revenue growth, 5Y average | −61.6% (better) | −65.3% |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Operating margin | −9391% | – |
| FCF margin | −7244% | – |
| Return on equity | – | −28.9% |
| Return on invested capital | – | −90.4% |
| Financial health | ||
| Debt / equity | – | 0.07 |
| Interest coverage | −181.0× | −28.3× (better) |
| Current ratio | 0.76 | 26.78 (better) |
| Altman Z-score | – | 2.51 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −29.3% |
| Shareholder yield | – | −29.3% |
| Ownership | ||
| Held by institutions | 0.00% | 77.9% |
| Held by insiders | 15.5% | 0.51% |
| Insider net buying, 12 months | – | $370K |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 21.8% |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- ALT stock overview
- ALT income statement
- ALT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.